High serum ferritin levels in newly diagnosed patients with myelodysplastic syndromes are associated with greater symptom severity


We examined the association between serum ferritin (SF) levels and patient-reported functional aspects and symptoms, as measured by the EORTC QLQ-C30, in newly diagnosed patients with myelodysplastic syndromes (MDS). Analysis was conducted on 497 MDS patients who were classified in two groups based on the SF value of 1000 ng/mL. Clinically relevant differences of patient-reported functional and symptom scales were evaluated and classified as small, medium and large, based on established thresholds. Multivariable linear regression analysis was performed to account for potential confounding factors. Patients with SF of ≥ 1000 ng/mL reported statistically significant and clinically relevant worse outcomes across various health domains. Dyspnea was the symptom indicating the largest difference and mean scores of patients with higher and lower SF levels were 40 and 24.3, respectively (p = 0.005), indicating a large clinically relevant difference (Δ = 15.7). Further research is needed to better understand the relationship between SF levels and specific health-related quality of life domains.

This is a preview of subscription content, log in to check access.

Fig. 1


  1. 1.

    Lefèvre C, Bondu S, Le Goff S, Kosmider O, Fontenay M. Dyserythropoiesis of myelodysplastic syndromes. Curr Opin Hematol. 2017;24(3):191–7.

    Article  Google Scholar 

  2. 2.

    Lyle L, Hirose A. Iron Overload in myelodysplastic syndromes: pathophysiology, consequences, diagnosis, and treatment. J Adv Pract Oncol. 2018;9(4):392–405.

    PubMed  PubMed Central  Google Scholar 

  3. 3.

    Isidori A, Borin L, Elli E, Latagliata R, Martino B, Palumbo G, et al. Iron toxicity - Its effect on the bone marrow. Blood Rev. 2018;32(6):473–9.

    CAS  Article  Google Scholar 

  4. 4.

    Gattermann N. Iron overload in myelodysplastic syndromes (MDS). Int J Hematol. 2018;107(1):55–63.

    CAS  Article  Google Scholar 

  5. 5.

    Wood JC. Guidelines for quantifying iron overload. Hematol Am Soc Hematol Edu. 2014;2014(1):210–5.

    Article  Google Scholar 

  6. 6.

    Malcovati L, Hellstrom-Lindberg E, Bowen D, Ades L, Cermak J, Del Canizo C, et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood. 2013;122(17):2943–64.

    CAS  Article  Google Scholar 

  7. 7.

    Caocci G, La Nasa G, Efficace F. Health-related quality of life and symptom assessment in patients with myelodysplastic syndromes. Expert Rev Hematol. 2009;2(1):69–80.

    Article  Google Scholar 

  8. 8.

    Lyons RM, Marek BJ, Paley C, Esposito J, McNamara K, Richards PD, et al. Relation between chelation and clinical outcomes in lower-risk patients with myelodysplastic syndromes: registry analysis at 5 years. Leuk Res. 2017;56:88–95.

    Article  Google Scholar 

  9. 9.

    Efficace F, Santini V, La Nasa G, Cottone F, Finelli C, Borin L, et al. Health-related quality of life in transfusion-dependent patients with myelodysplastic syndromes: a prospective study to assess the impact of iron chelation therapy. BMJ Support Palliat Care. 2016;6(1):80–8.

    Article  Google Scholar 

  10. 10.

    Efficace F, Cottone F, Oswald LB, Cella D, Patriarca A, Niscola P, et al. The IPSS-R more accurately captures fatigue severity of newly diagnosed patients with myelodysplastic syndromes compared with the IPSS index. Leukemia. 2020;2:13–7. https://doi.org/10.1038/s41375-41020-40746-41378.

    Article  Google Scholar 

  11. 11.

    Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–76.

    CAS  Article  Google Scholar 

  12. 12.

    Cocks K, King MT, Velikova G, Martyn St-James M, Fayers PM, Brown JM. Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. J Clin Oncol. 2011;29(1):89–96.

    Article  Google Scholar 

  13. 13.

    Fozza C, La Nasa G, Caocci G. The Yin and Yang of myelodysplastic syndromes and autoimmunity: the paradox of autoimmune disorders responding to therapies specific for MDS. Crit Rev Oncol Hematol. 2019;142:51–7.

    Article  Google Scholar 

  14. 14.

    Stauder R, Yu G, Koinig KA, Bagguley T, Fenaux P, Symeonidis A, et al. Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet study. Leukemia. 2018;32(6):1380–92.

    Article  Google Scholar 

  15. 15.

    Efficace F, Gaidano G, Breccia M, Criscuolo M, Cottone F, Caocci G, et al. Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes. Br J Haematol. 2015;168(3):361–70.

    Article  Google Scholar 

  16. 16.

    Hoeks M, Yu G, Langemeijer S, Crouch S, de Swart L, Fenaux P, et al. Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registry. Haematologica. 2020;105(3):640–51.

    Article  Google Scholar 

Download references


The authors gratefully acknowledge all patients who participated in the GIMEMA-PROMYS Study for dedicating their time in completing quality of life questionnaires and having contributed in advancing knowledge in this research area. We also acknowledge the important contribution over the years to the coordination of the Data Management activities of Dr. Francesco Sparano.



Author information




GC, FE designed the study and wrote the manuscript. FC, performed statistical analysis. All authors interpreted the data, read, commented on, and approved the final version of the manuscript.

Corresponding author

Correspondence to Fabio Efficace.

Ethics declarations

Conflict of interests

Massimo Breccia: Honoraria by Novartis, Pfizer, Incyte, Celgene, outside the submitted work. Fabio Efficace: personal fees from Bristol-Myers Squibb, Amgen, Orsenix, Incyte and Takeda; grants from Amgen, outside the submitted work. Mario Luppi: Advisory Boards: Novartis, Gilead Sci, Abbvie, Celgene, MSD, Sanofi, Daiichi-Sankyo; Travel Grant Gilead sci, outside the submitted work. Giuseppe A. Palumbo: Honoraria from Jannsen, Novartis, Celgene, Amgen, outside the submitted work. Marco Vignetti: personal fees from Jazz Healthcare Italy SRL, Amgen, Millennium Pharmaceuticals Inc., Celgene, Janssen, Novartis and Incyte, outside the submitted work.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Verify currency and authenticity via CrossMark

Cite this article

Caocci, G., Vignetti, M., Patriarca, A. et al. High serum ferritin levels in newly diagnosed patients with myelodysplastic syndromes are associated with greater symptom severity. Int J Hematol (2020). https://doi.org/10.1007/s12185-020-02920-y

Download citation


  • Serum ferritin
  • Myelodysplastic syndromes
  • Functional status
  • Quality of life
  • Symptoms
  • Transfusions